Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Oxulumis® Suprachoroidal Microcatherization of Triesence® in Diabetic Macular Edema

ClinicalTrials.gov ID: NCT05512962

Public ClinicalTrials.gov record NCT05512962. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 24, 2026, 7:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-Center, Randomized, Two-Arm, Parallel-Group, Single-masked, 24-week, Clinical Trial to Evaluate Safety and Tolerability of Two Dose Levels of Suprachoroidal Triamcinolone Acetonide Administered With the Oxulumis® Ophthalmic Administration Device in Subjects With Diabetic Macular Edema

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this clinical trial is to evaluate the safety and tolerability of suprachoroidal microcatheterization with the Oxulumis® device for a randomized treatment with two dose levels of Triesence® in subjects with Diabetic Macular Edema.

Study identification

NCT ID
NCT05512962
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Oxular Limited
Industry
Enrollment
25 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 30, 2022
Primary completion
Nov 29, 2023
Completion
Nov 29, 2023
Last update posted
Nov 19, 2024

2022 – 2023

United States locations

U.S. sites
6
U.S. states
3
U.S. cities
5
Facility City State ZIP Site status
California Retina Consultants Bakersfield California 93309
Retina Consultants of Minnesota Minneapolis Minnesota 55435
Austin Retina Associates Austin Texas 78705
Retina Consultants of Texas - The Woodlands Houston Texas 77384
Retina Consultants of Texas - Bellaire Houston Texas 77401
Retina Consultants of Texas - San Antonio San Antonio Texas 78240

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05512962, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 19, 2024 · Synced Sep 24, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05512962 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →